The Steroidal Alkaloid Tomatidine and Tomatidine-Rich Tomato Leaf Extract Suppress the Human Gastric Cancer-Derived 85As2 Cells In Vitro and In Vivo via Modulation of Interferon-Stimulated Genes.

The steroidal alkaloid tomatidine is an aglycone of α-tomatine, which is abundant in tomato leaves and has several biological activities. Tomatidine has been reported to inhibit the growth of cultured cancer cells in vitro, but its anti-cancer activity in vivo and inhibitory effect against gastric cancer cells remain unknown. We investigated the efficacy of tomatidine using human gastric cancer-derived 85As2 cells and its tumor-bearing mouse model and evaluated the effect of tomatidine-rich tomato leaf extract (TRTLE) obtained from tomato leaves. In the tumor-bearing mouse model, tumor growth was significantly inhibited by feeding a diet containing tomatidine and TRTLE for 3 weeks. Tomatidine and TRTLE also inhibited the proliferation of cultured 85As2 cells. Microarray data of gene expression analysis in mouse tumors revealed that the expression levels of mRNAs belonging to the type I interferon signaling pathway were altered in the mice fed the diet containing tomatidine and TRTLE. Moreover, the knockdown of one of the type I interferon-stimulated genes (ISGs), interferon α-inducible protein 27 (IFI27), inhibited the proliferation of cultured 85As2 cells. This study demonstrates that tomatidine and TRTLE inhibit the tumor growth in vivo and the proliferation of human gastric cancer-derived 85As2 cells in vitro, which could be due to the downregulation of ISG expression.

Vitamin D Activates Various Gene Expressions, Including Lipid Metabolism, in C2C12 Cells.

Vitamin D is a fat-soluble molecule, well known for its role in regulating calcium homeostasis in bone. It has become increasingly clear that it also has important effects in many other organs, including the skeletal muscle. In order to gain insight into the role of vitamin D in the skeletal muscle, we performed microarray analysis using C2C12 myoblasts treated with 1,25-dihydroxyvitamin D (1,25(OH)2D), active form of vitamin D. We found multiple genes upregulated by 1,25(OH)2D. Some of them, i.e., vitamin D receptor (Vdr), diacylglycerol O-acyltransferase (Dgat1 and Dgat2, the rate limiting steps of triacylglycerol acylation), and vascular endothelial growth factor A (Vegfa), were previously reported to be upregulated by 1,25(OH)2D in C2C12 cells. RT-qPCR analysis confirmed increased mRNA levels of Rarres2, Dio2, Tgm2, Lpl, Mdfi, Igfbp3, Dgat1, Crabp2, Gadd45a, Vagfa, Dgat2, C3, Ldhb, Cebpa, Igfbp5, Mrc2, Vdr. Thus, many genes, including lipid metabolism genes as well as genes related to muscle functions, appear to be upregulated by 1,25(OH)2D in muscle cells.

FOXO1 cooperates with C/EBPδ and ATF4 to regulate skeletal muscle atrophy transcriptional program during fasting.

Catabolic conditions, such as starvation, inactivity, and cancer cachexia, induce Forkhead box O (FOXO) transcription factor(s) expression and severe muscle atrophy via the induction of ubiquitin-proteasome system-mediated muscle proteolysis, resulting in frailty and poor quality of life. Although FOXOs are clearly essential for the induction of muscle atrophy, it is unclear whether there are other factors involved in the FOXO-mediated transcriptional regulation. As such, we identified FOXO-CCAAT/enhancer-binding protein δ (C/EBPδ) signaling pathway as a novel proteolytic pathway. By comparing the gene expression profiles of FOXO1-transgenic (gain-of-function model) and FOXO1,3a,4-/- (loss-of-function model) mice, we identified several novel FOXO1-target genes in skeletal muscle including Redd1, Sestrin1, Castor2, Chac1, Depp1, Lat3, as well as C/EBPδ. During starvation, C/EBPδ abundance was increased in a FOXOs-dependent manner. Notably, knockdown of C/EBPδ prevented the induction of the ubiquitin-proteasome system and decrease of myofibers in FOXO1-activated myotubes. Conversely, C/EBPδ overexpression in primary myotubes induced myotube atrophy. Furthermore, we demonstrated that FOXO1 enhances the promoter activity of target genes in cooperation with C/EBPδ and ATF4. This research comprehensively identifies novel FOXO1 target genes in skeletal muscle and clarifies the pathophysiological role of FOXO1, a master regulator of skeletal muscle atrophy.

Vitamin D and Sarcopenia: Potential of Vitamin D Supplementation in Sarcopenia Prevention and Treatment.

Skeletal muscle, the largest organ in the human body, accounting for approximately 40% of body weight, plays important roles in exercise and energy expenditure. In the elderly, there is often a progressive decline in skeletal muscle mass and function, a condition known as sarcopenia, which can lead to bedridden conditions, wheelchair confinement as well as reducing the quality of life (QOL). In developed countries with aging populations, the prevention and management of sarcopenia are important for the improvement of health and life expectancy in these populations. Recently, vitamin D, a fat-soluble vitamin, has been attracting attention due to its importance in sarcopenia. This review will focus on the effects of vitamin D deficiency and supplementation on sarcopenia.

FOXO1 suppresses PGC-1ß gene expression in skeletal muscles.

Peroxisome proliferator-activated receptor-gamma coactivator-1ß (PGC-1ß) is a transcriptional regulator whose increased expression activates energy expenditure-related genes in skeletal muscles. However, how PGC-1ß is regulated remains largely unclear. Here, we show that PGC-1ß gene expression is negatively correlated with the expression of a transcription factor, forkhead box protein O1 (FOXO1), whose expression is increased during muscle atrophy. In the skeletal muscles of FOXO1-overexpressing transgenic mice, PGC-1ß gene expression is decreased. Denervation or plaster cast-based unloading, as well as fasting, increases endogenous FOXO1 expression in skeletal muscles, with decreased PGC-1ß expression. In the skeletal muscles of FOXO1-knockout mice, the decrease in PGC-1ß expression caused by fasting was attenuated. Tamoxifen-inducible FOXO1 activation in C2C12 myoblasts causes a marked decrease of PGC-1ß expression. These findings together reveal that FOXO1 activation suppresses PGC-1ß expression. During atrophy with FOXO1 activation, decreased PGC-1ß may decrease energy expenditure and avoid wasting energy.

Metabolomic analysis of C2C12 myoblasts induced by the transcription factor FOXO1.

The transcription factor FOXO1 is considered to play roles in the regulation of energy metabolism in various tissues. To determine the metabolic changes occurring due to FOXO1 activation, we analyzed the metabolic profile of C2C12 myoblasts expressing a FOXO1-estrogen receptor fusion protein using capillary electrophoresis with electrospray ionization time-of-flight mass spectrometry (CE-TOFMS). In FOXO1-activated cells, the metabolite levels during glycolysis are higher and the gene expression of pyruvate dehydrogenase kinase, an enzyme that inhibits glucose utilization, is increased. In addition, the metabolite levels of numerous amino acids are decreased, with increased gene expression of branched chain amino acid metabolism enzymes. Our results suggest that FOXO1 suppresses glucose utilization and promotes the use of proteins/amino acids as energy sources in muscle cells, potentially during starvation.